Table 1. Comparison of diagnostic categories, splenomegaly, treatment, and disease progression in patients without BM fibrosis to those with any amount of BM fibrosis.
| MF-0 (N = 38) | MF1+ (N = 45) | P | |||
|---|---|---|---|---|---|
| Mean Age (Range) | 70.1 | 41–90 | 66.6 | 23–87 | 0.1 |
| M | 23 | 61% | 28 | 62% | 1 |
| F | 15 | 39% | 17 | 38% | |
| CMML Category | |||||
| 1 | 32 | 86% | 39 | 91% | 0.5 |
| 2 | 5 | 14% | 4 | 9% | |
| CMML Type | |||||
| MPN-type | 20 | 53% | 27 | 60% | 0.6 |
| MDS-type | 18 | 47% | 18 | 40% | |
| Splenomegaly | |||||
| Y | 11/38 | 29% | 26/45 | 58% | 0.016 |
| Disease Progression | 6/33 | 18% | 22/44 | 50% | 0.005 |
| Median Time to Disease Progression (m) | NR | 28.3 | 0.001 | ||
| Median overall survival (m) | 48.3 | 41.7 | 0.1 | ||
| Treatment | |||||
| Observation | 10/33 | 31% | 11/44 | 25% | 0.95 |
| Hypomethylating agents | 13/33 | 39% | 19/44 | 43% | |
| JAK inhibitor | 1/33 | 3% | 1/44 | 2% | |
| SCT | 9/33 | 27% | 13/44 | 30% | |
| Outcome | |||||
| DOD | 9 | 24% | 21 | 47% | 0.6 |
| ANED or AWD | 12 | 32% | 7 | 16% | |
| LFU or DUC or DUD | 17 | 45% | 17 | 38% | |
NR = not reached, SCT = stem cell transplant, DOD = died of disease, ANED = alive no evidence of disease, AWD = alive with disease, DUC = died of unknown cause, DUD = died of unrelated disease, LFU = lost to follow up.